A Star Is Born? HERCULES Data Shine At ASH For Ablynx's Caplacizumab

Strong Phase III HERCULES data mean Ablynx's caplacizumab is likely to sail through regulatory proceedings next year, becoming the first approved therapy for the rare blood disease, acquired thrombotic thrombocytopenic purpura.